BIND Therapeutics: Biotech Showcase (BIND Therapeutics) - Jan 30, 2016 - "BIND-014: mCRPC Trial (004) Meets Primary Endpoint and Suggests Differentiation"; "Substantial clinical activity: 71% of patients achieved rPFS of at least 6 months, Median rPFS of 9.9 months, Median OS was 13.4 months, with 10 patients censored, Confirmed ORR of 21% in 19 patients with measurable disease, 50% reduction in PSA in 30% of patients, Active despite 74% of patients with prior exposure to anti-androgen therapy"; "Well-tolerated: Clinically relevant reduction in toxicities"; "The safety and activity of BIND-014 suggest differentiation from docetaxel, including in patients who have prior exposure to anti-androgen therapy in view of the potential cross-resistance between anti-androgen therapy and docetaxel"
P2 data • Oncology • Prostate Cancer
|